secwatch.observer — SEC 8-K summary
======================================

Issuer:     LABCORP HOLDINGS INC. (LH)
CIK:        0000920148
Form:       8-K
Filed at:   2026-07-30T10:53:18+00:00
Accession:  0000920148-26-000162
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Labcorp Q2 revenue up 5.8% to $3.73B, adjusted EPS $4.99 beats; raises FY guidance
--------------------------------------------------------------------------------

- Q2 diluted EPS $3.64 vs $2.84 (+28.5%); adjusted EPS $4.99 vs $4.35 (+14.9%), beating prior guidance.
- Revenue $3.73B, up 5.8% YoY; Diagnostics Labs +5.5%, Biopharma +6.5%.
- Raised FY 2026 adjusted EPS guidance to $18.10-$18.55 (up $0.30 at midpoint); revenue growth 5.4%-6.3%.
- Board approved $1.0B increase in share repurchase authorization, total remaining $1.4B.
- Completed acquisitions of Parkview Health outreach services and Tribal Diagnostics; quarterly dividend $0.72.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/0000920148-26-000162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/lh-20260730.htm
  HTML page:      https://secwatch.observer/filing/0000920148-26-000162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer